Get it on Google Play

Cognition Therapeutics gets FDA alignment on Phase 3 DLB trial

October 22, 2026 6:00 AM EDT Send to a Friend
Cognition Therapeutics, Inc. (NASDAQ: CGTX) said it has reached alignment with the U.S. Food and Drug Administration on key elements ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login